Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 6/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6101670 | 0.87 | KDM4E (0.42) | ATMCA9CA12SMN1; SMN2CA1 | |
| SCHEMBL6098180 | 0.84 | UBE2N (0.45) | CA9CA12SMN1; SMN2CA1CA2 | |
| SCHEMBL6102056 | 0.82 | KCNN4 (0.51) | KCNN4ATMBRD4SMN1; SMN2KDM4E | |
| SCHEMBL5767355 | 0.81 | KDM4E (0.43) | ATMCA9BRD4CA12SMN1; SMN2 | |
| SCHEMBL5795396 | 0.81 | KDM4E (0.38) | ATMSMN1; SMN2KDM4EALDH1A1MAPT | |
| SCHEMBL5767865 | 0.81 | KCNN4 (0.46) | KCNN4CA9CA12SMN1; SMN2CA2 | |
| SCHEMBL6101735 | 0.81 | MAPT (0.55) | ATMSMN1; SMN2KDM4EALDH1A1GAA | |
| SCHEMBL6102290 | 0.78 | KMT2A (0.39) | ATMBRD4SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL5768848 | 0.77 | MAP4K4 (0.41) | ATMBRD4SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL5767322 | 0.77 | ALDH1A1 (0.37) | KCNN4CA9CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060211724-A1 | Hiv integrase inhibitors | VERSCHUEREN GASTON W | 2006-09-21 | — | — | US | disclosed |
| EP-1625130-A2 | HIV INTEGRASE INHIBITORS | Tibotec Pharmaceuticals Ltd. (IE) | 2006-02-15 | — | — | EP | disclosed |
| WO-2004096807-A2 | HIV INTEGRASE INHIBITORS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211724-A1 | Hiv integrase inhibitors | SULT1A1, SULT2A1, SULT1E1 | KCNN4 4777/4885ATM 4786/4885CA9 1900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.